Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status

Pia Roering; Arafat Siddiqui; Vanina D. Heuser; Swapnil Potdar; Piia Mikkonen; Jaana Oikkonen; Yilin Li; Sanna Pikkusaari; Krister Wennerberg; Johanna Hynninen; Seija Grenman; Kaisa Huhtinen; Annika Auranen; Olli Carpen; Katja Kaipio

doi:10.3389/fonc.2022.954430

Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status

Pia Roering, Arafat Siddiqui, Vanina D. Heuser, Swapnil Potdar, Piia Mikkonen, Jaana Oikkonen, Yilin Li, Sanna Pikkusaari, Krister Wennerberg, Johanna Hynninen, Seija Grenman, Kaisa Huhtinen, Annika Auranen, Olli Carpen, Katja Kaipio

Tutkimustuotos: Artikkelijulkaisu › Artikkeli › Tieteellinen › vertaisarvioitu

Alkuperäiskieli	englanti
Artikkeli	954430
Lehti	Frontiers in oncology
Vuosikerta	12
Sivumäärä	14
ISSN	2234-943X
DOI - pysyväislinkit	https://doi.org/10.3389/fonc.2022.954430
Tila	Julkaistu - 23 elok. 2022
OKM-julkaisutyyppi	A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä, vertaisarvioitu

Tieteenalat

3122 Syöpätaudit

Pääsy asiakirjaan

10.3389/fonc.2022.954430

fonc-12-954430Lopullinen julkaistu versio, 4,05 MBLisenssi: CC BY

Siteeraa tätä

Roering, P., Siddiqui, A., Heuser, V. D., Potdar, S., Mikkonen, P., Oikkonen, J., Li, Y., Pikkusaari, S., Wennerberg, K., Hynninen, J., Grenman, S., Huhtinen, K., Auranen, A., Carpen, O., & Kaipio, K. (2022). Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status. Frontiers in oncology , 12, Artikkeli 954430. https://doi.org/10.3389/fonc.2022.954430

@article{493adfb88eab4089af8d2cfe1c17fb10,

title = "Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status",

keywords = "adavosertib, patient-derived cell line, high-grade serous ovarian cancer (HGSOC), homologous recombination (HR), drug screen, platinum-resistant ovarian cancer, homologous recombination deficiency (HRD), homologous recombination proficient, REPLICATION STRESS, ABC TRANSPORTERS, PHASE-I, AZD1775, RESISTANT, GEMCITABINE, CARBOPLATIN, OLAPARIB, KINASE, 3122 Cancers",

author = "Pia Roering and Arafat Siddiqui and Heuser, {Vanina D.} and Swapnil Potdar and Piia Mikkonen and Jaana Oikkonen and Yilin Li and Sanna Pikkusaari and Krister Wennerberg and Johanna Hynninen and Seija Grenman and Kaisa Huhtinen and Annika Auranen and Olli Carpen and Katja Kaipio",

year = "2022",

month = aug,

day = "23",

doi = "10.3389/fonc.2022.954430",

language = "English",

volume = "12",

journal = "Frontiers in oncology ",

issn = "2234-943X",

publisher = "Frontiers Media SA",

}

Roering, P, Siddiqui, A, Heuser, VD, Potdar, S, Mikkonen, P, Oikkonen, J, Li, Y, Pikkusaari, S, Wennerberg, K, Hynninen, J, Grenman, S, Huhtinen, K, Auranen, A, Carpen, O & Kaipio, K 2022, 'Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status', Frontiers in oncology , Vuosikerta 12, 954430. https://doi.org/10.3389/fonc.2022.954430

Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status. / Roering, Pia; Siddiqui, Arafat; Heuser, Vanina D. et al.
julkaisussa: Frontiers in oncology , Vuosikerta 12, 954430, 23.08.2022.

Tutkimustuotos: Artikkelijulkaisu › Artikkeli › Tieteellinen › vertaisarvioitu

TY - JOUR

T1 - Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status

AU - Roering, Pia

AU - Siddiqui, Arafat

AU - Heuser, Vanina D.

AU - Potdar, Swapnil

AU - Mikkonen, Piia

AU - Oikkonen, Jaana

AU - Li, Yilin

AU - Pikkusaari, Sanna

AU - Wennerberg, Krister

AU - Hynninen, Johanna

AU - Grenman, Seija

AU - Huhtinen, Kaisa

AU - Auranen, Annika

AU - Carpen, Olli

AU - Kaipio, Katja

PY - 2022/8/23

Y1 - 2022/8/23

KW - adavosertib

KW - patient-derived cell line

KW - high-grade serous ovarian cancer (HGSOC)

KW - homologous recombination (HR)

KW - drug screen

KW - platinum-resistant ovarian cancer

KW - homologous recombination deficiency (HRD)

KW - homologous recombination proficient

KW - REPLICATION STRESS

KW - ABC TRANSPORTERS

KW - PHASE-I

KW - AZD1775

KW - RESISTANT

KW - GEMCITABINE

KW - CARBOPLATIN

KW - OLAPARIB

KW - KINASE

KW - 3122 Cancers

U2 - 10.3389/fonc.2022.954430

DO - 10.3389/fonc.2022.954430

M3 - Article

SN - 2234-943X

VL - 12

JO - Frontiers in oncology

JF - Frontiers in oncology

M1 - 954430

ER -